Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized Trial With Single Agent Trastuzumab or Lapatinib in Patients With Metastatic HER2-Overexpressing Breast Cancer

NCT00842998 is registered in ClinicalTrials.gov with Azienda Ospedaliera Ordine Mauriziano di Torino as lead sponsor.

NCT NCT00842998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00842998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized Trial With Single Agent Trastuzumab or Lapatinib in Patients With Metastatic HER2-Overexpressing Breast Cancer
Lead sponsor
Azienda Ospedaliera Ordine Mauriziano di Torino
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2009
Completion date
December 31, 2011
Enrollment
120 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer